VivoSeq
Other

Anxiolytic Effect

0

Pipeline Programs

0

Active Trials

0

Companies Involved

Anxiolytic Effect is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

3

clinical trials

Completed3 · 100%

Trial Activity

Sedative-Anxiolytic Effects on Simulated Driving Performance
Completed··Phase 4·NCT03297944·15 enrolled
Biomarker Changes and Anxiolytic Effects-Phase 2
Completed·UUniversity of Florida·Phase 2·NCT04565145·39 enrolled
Analgetic and Anxiolytic Effect of Preoperative Pregabalin
Completed··Phase 4·NCT00353704·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)